Page 3

  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Roche pays China-based biotech $70M for a new HER2 drug

    The drug, currently in Phase 1, is an oral medicine designed to cross the blood-brain barrier and better treat HER2 tumors that have spread to the brain.

  • A worker prepares ampoules of the Nuvaxovid vaccine against Covid-19 by Novavax in Berlin, Germany in February 2022.
    Image attribution tooltip
    Carsten Koall via Getty Images
    Image attribution tooltip

    Novavax cuts workforce by 25% as COVID vaccine sales fall

    The layoffs, which will affect hundreds of employees, are part of a major restructuring designed to reduce operational and research spending by as much as half.

  • a photo illustration showing packages of Mifepristone tablets
    Image attribution tooltip
    Anna Moneymaker/Getty Images via Getty Images
    Image attribution tooltip

    Abortion providers in 3 states sue over mifepristone restrictions

    The lawsuit seeks to remove safety restrictions on mifepristone or, alternatively, prevent further altering of access to the drug.

  • Alexis Borisy and Melanie Nallicheri of EQRx, at launch
    Image attribution tooltip
    Courtesy of EQRx
    Image attribution tooltip

    EQRx resets strategy, abandoning plans to disrupt drug pricing

    Launched in 2020 with a "radical" vision, EQRx ran into roadblocks that stymied its efforts to develop new medicines and undercut competitors on price.

  • Glass vials with orange caps sit on a pharmaceutical factory production line.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Catalent cuts outlook, delays results as it reveals new hurdles

    The pharmaceutical CDMO said it found “significant” issues with its forecasts over the past year, compounding manufacturing problems at three of its plants.

  • An image of the lab inside Recursion Pharmaceuticals.
    Image attribution tooltip
    Permission granted by Recursion Pharmaceuticals
    Image attribution tooltip

    Recursion to acquire two Canadian drug discovery startups

    The company agreed to buy Cyclica and Valence after winnowing down a list of more than 100 potential takeover targets, its CEO told BioPharma Dive. 

  • Image attribution tooltip
    Image attribution tooltip

    Former Rubius, Laronde CEO Cagnoni to join Incyte

    Six months after being named head of RNA-focused biotech Laronde, Pablo Cagnoni has left the buzzy startup to run Incyte’s R&D work.

  • A windowed building surrounded by trees with a sign "Baxter" in front
    Image attribution tooltip
    Tim Boyle via Getty Images
    Image attribution tooltip

    Baxter to sell biopharma unit to private equity for $4.25B

    The deal is the latest in a string of private equity-backed deals for contract development and manufacturing businesses in the pharmaceutical sector.

  • A photo of the street sign for Wall Street, in front of a row of American flags.
    Image attribution tooltip
    hapabapa via Getty Images
    Image attribution tooltip
    Emerging biotech

    Acelyrin follows Kenvue with largest IPO for a biotech startup since 2021

    The $540 million offering adds to evidence suggesting young drugmakers may need to be well into clinical testing before going public in the current market. 

    Updated May 8, 2023
  • Two young boys are seen posing for a photograph with a snake.
    Image attribution tooltip
    Permission granted by Susan and Chris Finazzo
    Image attribution tooltip
    Deep Dive

    ‘The luckiest of the unlucky’: A Duchenne gene therapy brings hope to families — and tests the FDA

    FDA advisers voted 8-6 in support of the agency approving a treatment that patient advocates and doctors believe to be a breakthrough for a deadly disease.

  • A photo of a sign inside an Apellis Pharmaceuticals building
    Image attribution tooltip
    Courtesy of Apellis Pharmaceuticals
    Image attribution tooltip

    Apellis reports strong start for new vision loss drug

    Higher-than-expected sales of the geographic atrophy therapy Syfovre pushed shares in Apellis higher, and could add to speculation about a takeover.